ArticleNeurodegenerative disease management
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
Article in Neurodegenerative disease management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Persons With Cognitive Impairment and Care Partner Motivations and Experiences of Undergoing an Amyloid Scan: A Systematic Review of Qualitative Studies.The Gerontologist · 2024Pooled it
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.Alzheimer's research & therapy · 2016Pooled it
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Disclosure of Alzheimer's disease blood-based biomarker results in a primary care setting: Opportunities and challenges.The journal of prevention of Alzheimer's disease · 2025Review
- Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Ethics of early detection of disease risk factors: A scoping review.BMC medical ethics · 2024Article
- Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.Neurology · 2023Article
- Biomarkers of aging.Science China. Life sciences · 2023Review
- Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease.Journal of personalized medicine · 2020Review
- Article
- Added value of amyloid PET in individualized risk predictions for MCI patients.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.Alzheimer's research & therapy · 2019Article
- Article
- Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Journal of bioethical inquiry · 2019Article
- Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.Alzheimer's research & therapy · 2018Article
- Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.JAMA neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PET ligands that bind with high specificity to amyloid plaques represent a major breakthrough in Alzheimer's disease (AD) research. Amyloid neuroimaging is now approved by the US FDA to aid in the diagnosis of AD, and is being used to identify amyloid-positive but asymptomatic individuals for secondary AD prevention trials. The use of amyloid neuroimaging in preclinical populations raises important ethical and practical challenges, including determining appropriate uses of this technology, evaluating the potential benefits and harms of disclosing results, and communicating effectively about testing with patients and family members. Emerging policy issues also require consideration (e.g., legal safeguards for biomarker-positive individuals). Further research is needed to inform effective and ethical implementation and regulation of amyloid imaging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.